ECSP088416A - Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida - Google Patents
Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamidaInfo
- Publication number
- ECSP088416A ECSP088416A EC2008008416A ECSP088416A ECSP088416A EC SP088416 A ECSP088416 A EC SP088416A EC 2008008416 A EC2008008416 A EC 2008008416A EC SP088416 A ECSP088416 A EC SP088416A EC SP088416 A ECSP088416 A EC SP088416A
- Authority
- EC
- Ecuador
- Prior art keywords
- preparation
- diazapanil
- piperacinil
- benzamida
- derivatives
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000000543 Histamine Receptors Human genes 0.000 abstract 1
- 108010002059 Histamine Receptors Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- MCBOTNKJOSKNFJ-UHFFFAOYSA-N n-(diazepan-1-yl)benzamide Chemical class C=1C=CC=CC=1C(=O)NN1CCCCCN1 MCBOTNKJOSKNFJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La La presente invención está dirigida a procedimientos novedosos para la preparación de piperacinil y diazepanil benzamidas sustituidas, útiles para el tratamiento de trastornos y condiciones mediadas por el receptor de la histamina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73194105P | 2005-10-31 | 2005-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP088416A true ECSP088416A (es) | 2008-05-30 |
Family
ID=37766699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2008008416A ECSP088416A (es) | 2005-10-31 | 2008-04-30 | Procedimientos novedosos para la preparacion de derivados de piperacinil y diazapanil benzamida |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7728129B2 (es) |
| EP (2) | EP2404911A1 (es) |
| JP (1) | JP2009513702A (es) |
| KR (1) | KR20080067365A (es) |
| CN (1) | CN101389617A (es) |
| AR (1) | AR056750A1 (es) |
| AU (1) | AU2006309077A1 (es) |
| BR (1) | BRPI0617947A2 (es) |
| CA (1) | CA2628210A1 (es) |
| CR (1) | CR10037A (es) |
| EA (2) | EA201001799A1 (es) |
| EC (1) | ECSP088416A (es) |
| IL (1) | IL190963A0 (es) |
| NO (1) | NO20082459L (es) |
| NZ (1) | NZ567357A (es) |
| SV (1) | SV2009002893A (es) |
| TW (1) | TW200736239A (es) |
| WO (1) | WO2007053427A2 (es) |
| ZA (1) | ZA200804732B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0324159D0 (en) | 2003-10-15 | 2003-11-19 | Glaxo Group Ltd | Novel compounds |
| ES2620818T3 (es) * | 2006-12-14 | 2017-06-29 | Janssen Pharmaceutica N.V. | Procedimiento para la preparación de derivados de piperazinil y diazepanil benzamida |
| WO2009030716A1 (en) | 2007-09-06 | 2009-03-12 | Glaxo Group Limited | Piperazine derivative having affinity for the histamine h3 receptor |
| CN111610246B (zh) * | 2019-02-25 | 2023-05-12 | 中国科学院上海有机化学研究所 | 用于质谱检测的羧基衍生化试剂组合物及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
| US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
| SK5202000A3 (en) | 2000-04-07 | 2001-12-03 | Slovakofarma As | Method for the preparation of (e)-n-(6,6-dimethyl-2-hepten-4- inyl)-n-methyl-1-naphthalenemethylamine (terbinaphin) |
| EP1296939B1 (de) * | 2000-07-05 | 2005-11-09 | Basf Aktiengesellschaft | Verfahren zur herstellung von trioximderivaten |
| DE60209704T2 (de) * | 2001-05-22 | 2006-11-16 | Pfizer Products Inc., Groton | Neue kristallforme von azithromycin |
| US6548670B1 (en) | 2001-07-19 | 2003-04-15 | Air Products And Chemicals, Inc. | Methods for preparing 5- and 6-benzyl-functionalized quinoxalines |
| US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
| ATE449766T1 (de) * | 2002-10-23 | 2009-12-15 | Janssen Pharmaceutica Nv | Piperazinyl- und diazapanylbenzamide und- benzothioamide |
| WO2005021525A1 (en) * | 2003-08-27 | 2005-03-10 | Janssen Pharmaceutica, N.V. | Aryl piperidine amides |
| AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| PT1924585E (pt) * | 2005-08-29 | 2012-01-19 | Sanofi Aventis Us Llc | Nova forma cristalina de um derivado de piridazino[4,5-b]indole |
| DE602006019822D1 (de) * | 2005-09-13 | 2011-03-10 | Sicor Inc | Reines rocuroniumbromid |
| KR20090064400A (ko) * | 2006-09-28 | 2009-06-18 | 머크 앤드 캄파니 인코포레이티드 | Hdac 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-hdac 억제제 킬레이트 착물의 약제학적 조성물 |
| US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| EP2160394A1 (en) * | 2007-05-22 | 2010-03-10 | Ultimorphix Technologies B.v. | Tenofovir disoproxil hemi-fumaric acid co-crystal |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
-
2006
- 2006-10-26 EP EP11183817A patent/EP2404911A1/en not_active Withdrawn
- 2006-10-26 CA CA002628210A patent/CA2628210A1/en not_active Abandoned
- 2006-10-26 KR KR1020087013062A patent/KR20080067365A/ko not_active Ceased
- 2006-10-26 US US11/553,158 patent/US7728129B2/en active Active
- 2006-10-26 BR BRPI0617947-9A patent/BRPI0617947A2/pt not_active IP Right Cessation
- 2006-10-26 AU AU2006309077A patent/AU2006309077A1/en not_active Abandoned
- 2006-10-26 EP EP06826786A patent/EP1951700A2/en not_active Withdrawn
- 2006-10-26 NZ NZ567357A patent/NZ567357A/en not_active IP Right Cessation
- 2006-10-26 CN CNA2006800406803A patent/CN101389617A/zh active Pending
- 2006-10-26 JP JP2008538930A patent/JP2009513702A/ja active Pending
- 2006-10-26 WO PCT/US2006/041859 patent/WO2007053427A2/en not_active Ceased
- 2006-10-26 EA EA201001799A patent/EA201001799A1/ru unknown
- 2006-10-26 EA EA200801239A patent/EA014905B1/ru unknown
- 2006-10-30 TW TW095139961A patent/TW200736239A/zh unknown
- 2006-10-31 AR ARP060104773A patent/AR056750A1/es not_active Application Discontinuation
-
2008
- 2008-04-17 IL IL190963A patent/IL190963A0/en unknown
- 2008-04-30 SV SV2008002893A patent/SV2009002893A/es not_active Application Discontinuation
- 2008-04-30 EC EC2008008416A patent/ECSP088416A/es unknown
- 2008-05-30 NO NO20082459A patent/NO20082459L/no not_active Application Discontinuation
- 2008-05-30 CR CR10037A patent/CR10037A/es not_active Application Discontinuation
- 2008-05-30 ZA ZA200804732A patent/ZA200804732B/xx unknown
-
2010
- 2010-04-19 US US12/762,912 patent/US20100197689A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA200801239A1 (ru) | 2008-08-29 |
| CR10037A (es) | 2008-11-24 |
| EA014905B1 (ru) | 2011-02-28 |
| US20070197508A1 (en) | 2007-08-23 |
| IL190963A0 (en) | 2008-12-29 |
| BRPI0617947A2 (pt) | 2011-08-09 |
| SV2009002893A (es) | 2009-06-18 |
| US20100197689A1 (en) | 2010-08-05 |
| AU2006309077A1 (en) | 2007-05-10 |
| NZ567357A (en) | 2011-05-27 |
| JP2009513702A (ja) | 2009-04-02 |
| ZA200804732B (en) | 2009-11-25 |
| NO20082459L (no) | 2008-07-22 |
| CN101389617A (zh) | 2009-03-18 |
| EP2404911A1 (en) | 2012-01-11 |
| US7728129B2 (en) | 2010-06-01 |
| WO2007053427A2 (en) | 2007-05-10 |
| KR20080067365A (ko) | 2008-07-18 |
| WO2007053427A3 (en) | 2007-07-12 |
| EP1951700A2 (en) | 2008-08-06 |
| EA201001799A1 (ru) | 2011-06-30 |
| AR056750A1 (es) | 2007-10-24 |
| CA2628210A1 (en) | 2007-05-10 |
| TW200736239A (en) | 2007-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099405A (es) | Procedimiento para la preparación de derivados benzimida piperacinilo y diazepanilo | |
| PA8784001A1 (es) | Oxazolidinonas sustituidas y su uso | |
| CO6311079A2 (es) | Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer | |
| UY30931A1 (es) | Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso | |
| ECSP077296A (es) | Fenilaminotiazoles sustituidos y su uso | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| SMT201200017B (it) | Nuovi antagonisti P2X7R e il loro uso. | |
| NI200700032A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| ATE517869T1 (de) | Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon | |
| BRPI0820668A2 (pt) | Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina | |
| DOP2011000064A (es) | Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilaminio-metil] benzamida (ms-275) | |
| ECSP11011482A (es) | Piperidinas sustituidas | |
| CR10036A (es) | Procedimientos para la preparación de derivados de ciclopropilamida | |
| GT200600081A (es) | Derivados de acetilenno | |
| CR10037A (es) | Procedimientos novedosos para la preparación de derivados de piperacinil y diazapanil benzamida | |
| DOP2003000587A (es) | AGONISTAS DEL RECEPTOR ß3-ADRENERGICO | |
| CY1110087T1 (el) | Μεθοδοι παρασκευης ενωσεων που περιεχουν πυρραζολιο | |
| DK1893597T3 (da) | AMPA-receptorpotentiatorer | |
| DOP2005000174A (es) | Fenilaminotiazoles sustituidos y su uso | |
| GT200800195A (es) | Procedimiento para la preparación de derivados de ciclopropilamida |